These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 39076864)
1. Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand? Rakocevic J; Dobric M; Borovic ML; Milutinovic K; Milenkovic S; Tomasevic M Rev Cardiovasc Med; 2023 Jan; 24(1):10. PubMed ID: 39076864 [TBL] [Abstract][Full Text] [Related]
2. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]
3. The Role of Colchicine in Acute Coronary Syndromes. Vaidya K; Martínez G; Patel S Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392 [TBL] [Abstract][Full Text] [Related]
4. Hegemony of inflammation in atherosclerosis and coronary artery disease. Attiq A; Afzal S; Ahmad W; Kandeel M Eur J Pharmacol; 2024 Mar; 966():176338. PubMed ID: 38242225 [TBL] [Abstract][Full Text] [Related]
6. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Koenig W Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367 [TBL] [Abstract][Full Text] [Related]
9. Atherosclerosis: perspectives of anti-inflammatory therapy. Nasonov EL; Popkova TV Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884 [TBL] [Abstract][Full Text] [Related]
10. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk. Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836 [TBL] [Abstract][Full Text] [Related]
11. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
12. Inflammation as a Therapeutic Target in Atherosclerosis. Nguyen MT; Fernando S; Schwarz N; Tan JT; Bursill CA; Psaltis PJ J Clin Med; 2019 Jul; 8(8):. PubMed ID: 31357404 [TBL] [Abstract][Full Text] [Related]
13. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Ridker PM Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745 [TBL] [Abstract][Full Text] [Related]
17. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia. Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472 [TBL] [Abstract][Full Text] [Related]
18. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis. Kottoor SJ; Arora RR J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850 [TBL] [Abstract][Full Text] [Related]
19. Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. Montarello NJ; Nguyen MT; Wong DTL; Nicholls SJ; Psaltis PJ Cardiovasc Drugs Ther; 2022 Apr; 36(2):347-362. PubMed ID: 33170943 [TBL] [Abstract][Full Text] [Related]
20. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition. Satish M; Agrawal DK Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]